Please assess the completion status of the following clinical trial:

Trial Title: Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Four to fifteen AKs on the face~* histologically confirmed presence of abnormal architecture and satellite atypical keratinocytes in the epidermis, in clinically normal tissue samples of photodamaged skin adjacent to AKs~* at least one previously treated nonmelanoma skin cancer (NMSC) on the head and/or neck area within the past five years~Exclusion Criteria:~* Pregnancy~* history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis~* lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the Treatment Area~* skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy~* Subject is immunosuppressed~* unsuccessful outcome from previous ALA-PDT therapy~* currently enrolled in an investigational drug or device study~* has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment~* known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)~* has an active herpes simplex infection OR a history of 2 or more outbreaks within the past 12 months, on the face~* use of the following topical preparations on the extremity to be treated:~  * Keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days~ * Retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks~ * Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-fluorouracil (5-FU), diclofenac, ingenol mebutate, imiquimod or other topical treatments for AK within 8 weeks~* use of systemic retinoid therapy within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALA X3 (Type: EXPERIMENTAL): Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
- VEH (Type: PLACEBO_COMPARATOR): Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
- ALA X2 (Type: EXPERIMENTAL): Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).